share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  08/15 15:52

Moomoo AI 已提取核心信息

Cybin Inc. (Cybin), a biotechnology company, announced the filing of Form 6-K with the U.S. Securities and Exchange Commission (SEC) for August 2024. The report, signed by CEO Doug Drysdale, includes details of the upcoming Annual and Special Meeting of Shareholders scheduled for August 27, 2024. Shareholders will vote on several key issues, including the appointment of Zeifmans LLP as the auditor, the election of directors, a proposed consolidation of common shares by a ratio of up to 50:1, amendments to the Equity Incentive Plan, the Amended and Restated Rights Plan, and amendments to common share purchase warrants. The meeting will be held virtually, and shareholders can attend and vote online. The management information circular provides comprehensive information on the matters to be voted on, including the background and qualifications of director nominees, and outlines the procedures for proxy voting and appointing proxyholders.
Cybin Inc. (Cybin), a biotechnology company, announced the filing of Form 6-K with the U.S. Securities and Exchange Commission (SEC) for August 2024. The report, signed by CEO Doug Drysdale, includes details of the upcoming Annual and Special Meeting of Shareholders scheduled for August 27, 2024. Shareholders will vote on several key issues, including the appointment of Zeifmans LLP as the auditor, the election of directors, a proposed consolidation of common shares by a ratio of up to 50:1, amendments to the Equity Incentive Plan, the Amended and Restated Rights Plan, and amendments to common share purchase warrants. The meeting will be held virtually, and shareholders can attend and vote online. The management information circular provides comprehensive information on the matters to be voted on, including the background and qualifications of director nominees, and outlines the procedures for proxy voting and appointing proxyholders.
生物技术公司Cybin Inc.（Cybin）宣布将于2024年8月向美国证券交易委员会（SEC）提交6-K表格。该报告由首席执行官Doug Drysdale签署，包括即将于2024年8月27日召开的股东年度和特别会议的详细信息。股东将就多个关键问题进行投票，包括任命Zeifmans LLP为审计师、董事会选举、按比例高达50：1的普通股合并提案、股权激励计划、修订后的权利计划以及普通股购买认股权证的修订案。会议将以虚拟方式举行，股东可以在线参加和投票。管理信息通函提供有关投票事项的全面信息，包括董事提名人的背景和资格，并概述了代理投票和任命代理人的程序。
生物技术公司Cybin Inc.（Cybin）宣布将于2024年8月向美国证券交易委员会（SEC）提交6-K表格。该报告由首席执行官Doug Drysdale签署，包括即将于2024年8月27日召开的股东年度和特别会议的详细信息。股东将就多个关键问题进行投票，包括任命Zeifmans LLP为审计师、董事会选举、按比例高达50：1的普通股合并提案、股权激励计划、修订后的权利计划以及普通股购买认股权证的修订案。会议将以虚拟方式举行，股东可以在线参加和投票。管理信息通函提供有关投票事项的全面信息，包括董事提名人的背景和资格，并概述了代理投票和任命代理人的程序。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间